BCTXF News and Press, BriaCell Therapeutics From 03/21/19

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) , a biotechnology company developing targeted, safe treatments for cancer, on Wednesday announced its intention to complete a non-brokered private placement of up to 20,000,000 common shares of the company at a price of C$0.10 each for gross p...

BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to...

New, frozen formulation of ready-to-inject Bria-IMT increases potency, simplifies logistics and is expected to reduce cost-per-dose BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Founder and Director Dr....

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) , a biotechnology company developing targeted, safe treatments for cancer, this morning announced the appointment of Dr. Rebecca Taub, M.D., and Vaughn C. Embro-Pantalony to its board of directors. Dr. Saeid Babaei, Rahoul Sharan and Mar...

BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announce...

Immuno-oncology-focused biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently secured support for its novel immunotherapy clinical research in the form of an equity investment of C$500,000 by the company’s recently appointed director, Jamieson Bondarenko ( h...

The company has announced an increase in the potency of its lead immunotherapy candidate, Bria-IMT, through cryopreservation The frozen formula simplifies logistics and makes it possible for the immunotherapy to reach patients across long distances without a compromise in the safety or ef...

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its i...

Through its advancement of Bria-IMT and Bria-OTS, BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is developing cutting-edge treatments to address cancer patient needs. A recent article discussing the company reads, “The imminent clinical use of a novel, frozen formulation of Bria-IMT...

Proprietary targeted immunotherapy technology personalized to match unmet needs of advanced breast cancer patients Ongoing clinical studies of lead candidate, Bria-IMT, continue to show robust biological activity, excellent safety profile Breast cancer is one of the most commonly diagno...